Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17547644 | 0.84 | TUBB4A (0.55) | MAPTALDH1A1SMN1; SMN2LMNAMAOB | |
| SCHEMBL17547645 | 0.82 | MAOB (0.56) | MAPTALDH1A1SMN1; SMN2LMNAMAOB | |
| SCHEMBL16264023 | 0.81 | MAOB (0.67) | MAPTALDH1A1SMN1; SMN2MAOBMIF | |
| SCHEMBL17547649 | 0.78 | MAOB (0.50) | MAOBMIF | |
| SCHEMBL16264022 | 0.77 | ALDH1A1 (0.66) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL17547643 | 0.73 | MAOB (0.47) | MAPTALDH1A1SMN1; SMN2LMNAMAOB | |
| SCHEMBL17547648 | 0.73 | MAPT (0.61) | MAPTALDH1A1LMNAMAOBHPGD | |
| SCHEMBL17536657 | 0.73 | MAOB (0.67) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL17547651 | 0.73 | TUBB1 (0.59) | MAPTALDH1A1SMN1; SMN2LMNAMAOB | |
| SCHEMBL17547642 | 0.73 | MAOB (0.67) | MAPTALDH1A1SMN1; SMN2LMNAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707445-B2 | Composition for blocking angiogenesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017091473-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707445-B2 | Composition for blocking angiogenesis | FLT4, KDR, VEGFA | MAPT 2741/4885ALDH1A1 3065/4885SMN1; SMN2 4467/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAPT 3088/4885ALDH1A1 1077/4885SMN1; SMN2 2068/4885 |
| US-20210228538-A1 | COMPOSITION FOR BLOCKING ANGIOGENESIS | FLT4, KDR, VEGFA | MAPT 2741/4885ALDH1A1 3065/4885SMN1; SMN2 4467/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAPT 3088/4885ALDH1A1 1077/4885SMN1; SMN2 2068/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAPT 3088/4885ALDH1A1 1077/4885SMN1; SMN2 2068/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAPT 3088/4885ALDH1A1 1077/4885SMN1; SMN2 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.